In particular, BAP1 and PBMR1 mutations have been associated with bone metastases and worse survival in extrahepatic CC (ECC), while KRAS and TP53 mutations, as well as loss of PTEN expression, with worse survival in intrahepatic CC (ICC) [32, 38, 39]. Here, KRAS is linked to intrahepatic cholangiocarcinoma.